FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington,	D.C.	20549	
-------------	------	-------	--

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
--

OMB APPROVAL									
OMB Number: 3235-0287									
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Altschuler Steven</u>				2. Issuer Name <b>and</b> Ticker or Trading Symbol Orchard Therapeutics plc [ ORTX ]						(Ch	Relationship eck all appli X Directo	cable)	g Pers	son(s) to Issi 10% Ov			
(Last)	`	rst) IERAPEUTICS	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 06/17/2020							Officer (give title below)			Other (s below)	pecify	
108 CANNON STREET				4.1	If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable					
(Street)	N X	)	EC4N 6EU								X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(Si	ate)	(Zip)														
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
Date				Fransaction te onth/Day/Ye	Execution Date,		Code (Instr. 5)				Benefici	es For ally (D) following (I) (I		m: Direct or Indirect Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Cor			Code	v	Amount	(A) or (D)	Price	Transac (Instr. 3	tion(s)			1130.4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
Derivative Conversion Date Execution Date, or Exercise (Month/Day/Year) if any		Code (	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expiration Date (Month/Day/Year) Amc Section Und Deri			7. Title and Amount of Securities Underlying Derivative Securit (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Code	v	(A)	(D)	Date Exercisable		xpiration ate	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$7.81	06/17/2020		A		35,000		(1)	0	6/16/2030	Ordinary Shares <sup>(2)</sup>	35,000	\$0.00	35,000	0	D	

## **Explanation of Responses:**

- 1. All of the shares subject to this option vest upon the earlier to occur of June 17, 2021 or the date of the 2021 Annual General Meeting of the Company.
- 2. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

## Remarks:

/s/ Frank Thomas, as attorneyin-fact for Steven Altschuler

06/19/2020

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.